Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
70458-92-3
Molecular formula
C17H20FN3O3
Molecular weight
333.36 g/mol
Drug class
Fluoroquinolone antibacterialbacterial DNA gyrase and topoisomerase IV inhibitor
Mechanism of action
Inhibits bacterial type II topoisomerases, DNA gyrase and topoisomerase IV, trapping enzyme-DNA cleavage complexes and preventing DNA replication and transcription. This produces bactericidal activity against susceptible Gram-negative and Gram-positive organisms.
Indications / reported uses
Historically used for susceptible systemic bacterial infections, including selected urinary, gastrointestinal and respiratory infections, where authorised.
Use is restricted or withdrawn in some jurisdictions because of potentially disabling and long-lasting fluoroquinolone adverse effects; follow current local authorisation and product information.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Pefloxacin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pefloxacin Permitted Daily Exposure (PDE) report (the Pefloxacin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pefloxacin Occupational Exposure Limit (OEL) report (the Pefloxacin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.